Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Total Liabilities: 2013-2025

Historic Total Liabilities for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to $182.8 million.

  • Theravance Biopharma's Total Liabilities rose 7.23% to $182.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $182.8 million, marking a year-over-year increase of 7.23%. This contributed to the annual value of $178.6 million for FY2024, which is 5.69% up from last year.
  • As of Q3 2025, Theravance Biopharma's Total Liabilities stood at $182.8 million, which was down 9.15% from $201.2 million recorded in Q2 2025.
  • Theravance Biopharma's Total Liabilities' 5-year high stood at $748.3 million during Q1 2021, with a 5-year trough of $165.6 million in Q4 2022.
  • Moreover, its 3-year median value for Total Liabilities was $169.0 million (2023), whereas its average is $174.2 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first plummeted by 76.79% in 2022, then rose by 19.51% in 2025.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Total Liabilities stood at $713.4 million in 2021, then crashed by 76.79% to $165.6 million in 2022, then climbed by 2.06% to $169.0 million in 2023, then increased by 5.69% to $178.6 million in 2024, then climbed by 7.23% to $182.8 million in 2025.
  • Its last three reported values are $182.8 million in Q3 2025, $201.2 million for Q2 2025, and $177.6 million during Q1 2025.